Comparison of Effectiveness of Etoricoxib and Diclofenac on Pain and Perioperative Sequelae After Surgical Avulsion of Mandibular Third Molars: A Randomized, Controlled, Clinical Trial.


Journal

The Clinical journal of pain
ISSN: 1536-5409
Titre abrégé: Clin J Pain
Pays: United States
ID NLM: 8507389

Informations de publication

Date de publication:
11 2019
Historique:
pubmed: 2 8 2019
medline: 21 10 2020
entrez: 2 8 2019
Statut: ppublish

Résumé

The objective of this analysis was to compare the efficacy of etoricoxib and diclofenac in the management of perioperative sequelae following impacted mandibular third molar surgery. Ninety-seven patients who needed surgical avulsion of an impacted mandibular third molar were chosen for the study. All patients were randomly allocated to receive one of the following treatments, twice a day for 5 days after surgery: placebo (n=33), diclofenac (n=32), or etoricoxib (n=32). The primary outcome evaluated was postoperative pain, recorded by each patient and evaluated using the Visual Analogue Scale score. The secondary outcomes chosen were, compared with preoperative ones, changes in postoperative swelling and maximum mouth opening. Compared with placebo, treatment with etoricoxib and diclofenac demonstrated an enhancement in the primary outcome. Furthermore, when compared with the other groups, patients who had undergone etoricoxib presented a significant median reduction in postoperative pain at 2 hours (P<0.001), 12 hours (P=0.025), and at 48 hours (P=0.018) after surgery. Moreover, the linear regression analysis showed that diclofenac and etoricoxib determined a significant influence on Visual Analogue Scale at 2, 6, 12, 24, 48 hours and at 10 days after surgery. There were no differences in swelling and maximum mouth opening values between groups. This study demonstrated that both treatments were effective. However, treatment with etoricoxib showed a greater reduction in the incidence and severity of postoperative pain following third molar surgery compared with diclofenac and placebo.

Identifiants

pubmed: 31368908
doi: 10.1097/AJP.0000000000000748
doi:

Substances chimiques

Anti-Inflammatory Agents, Non-Steroidal 0
Diclofenac 144O8QL0L1
Etoricoxib WRX4NFY03R

Types de publication

Comparative Study Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

908-915

Auteurs

Gaetano Isola (G)

Department of General Surgery and Surgical-Medical Specialties, School of Dentistry, University of Catania, Catania.

Giovanni Matarese (G)

Department of Biomedical and Odontostomatological Sciences and Morphological and Functional Images, School of Dentistry.

Angela Alibrandi (A)

Unit of Statistical and Mathematical Sciences, Department of Economics, University of Messina, Messina.

Domenico Dalessandri (D)

Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Dental School, University of Brescia, Brescia.

Marco Migliorati (M)

Department of Odontostomatology, School of Dentistry, University of Genova, Genova, Italy.

Eugenio Pedullà (E)

Department of General Surgery and Surgical-Medical Specialties, School of Dentistry, University of Catania, Catania.

Ernesto Rapisarda (E)

Department of General Surgery and Surgical-Medical Specialties, School of Dentistry, University of Catania, Catania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH